Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Selective Treatment According to Molecular Subtype of Prostate Cancer (STAMP)

This is an open-label study that includes three substudies of random distribution. First, a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers. Depending on the expression of these markers, the patients will be characterize as group 1 (Luminal …

testosterone
serum testosterone
  • 1 views
  • 14 Feb, 2022
  • 1 location
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE)

This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with …

breast cancer
measurable disease
liver metastasis
metastasis
immunohistochemistry
  • 0 views
  • 11 May, 2022
  • 2 locations
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. The aim of this study is to prospectively

braf v600e mutation
advanced melanoma
KRAS
advanced lung cancer
vemurafenib
  • 10 views
  • 12 Mar, 2022
  • 1 location
Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer (RESISTYR)

, erlotinib. Furthermore, a link between TKI concentration and ctDNA concentration was demonstrated in a pilot study by Garlan et al. in 11 patients treated for melanoma with vemurafenib. The impact

lung carcinoma
lung cancer
osimertinib
adenocarcinoma
cancer
  • 0 views
  • 09 May, 2022
  • 3 locations